Intro

This chapter examines a three-year study revealing Eli Lilly's ZEP Bound significantly reduces diabetes risk by 94% in patients. It underscores the importance of long-term data on GLP-1 drugs, showcasing their enduring benefits in weight management and chronic disease prevention.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.